Risultati della ricerca - Laura Van't Veer
- Mostra 1 - 20 risultati su 94
- Vai alla pagina seguente
-
1
-
2
The MINDACT trial: The first prospective clinical validation of a genomic tool di Fátima Cardoso, Martine Piccart, Laura Van't Veer, Emiel J. Rutgers
Pubblicazione 2007Artigo -
3
-
4
-
5
Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma di Patti Curl, Igor Vujic, Laura van ‘t Veer, Susana Ortiz‐Urda, James G. Kahn
Pubblicazione 2014Artigo -
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer di Rob Michalides, Alexander Griekspoor, Astrid Balkenende, Desirée Verwoerd, Lennert Janssen, Kees Jalink, Arno Floore, Arno Velds, Laura van 't Veer, Jacques Neefjes
Pubblicazione 2004Artigo -
16
-
17
-
18
-
19
A combined oncogenic pathway signature of<i>BRAF</i>,<i>KRAS</i>and<i>PI3KCA</i>mutation improves colorectal cancer classification and cetuximab treatment prediction di Sun Tian, Iris Simón, Vı́ctor Moreno, Paul Roepman, Josep Tabernero, Mireille H.J. Snel, Laura van’t Veer, Ramón Salazar, René Bernards, Gabriel Capellà
Pubblicazione 2012Artigo -
20
Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes di Mahasti Saghatchian, Stella Mook, Giancarlo Pruneri, Giuseppe Viale, Annuska M. Glas, Sylvie Guérin, Fátima Cardoso, Martine Piccart, Thomas Tursz, Suzette Delaloge, Laura van’t Veer
Pubblicazione 2013Artigo
Strumenti per la ricerca:
Soggetti correlati
Cancer
Medicine
Breast cancer
Internal medicine
Oncology
Biology
Gene
Genetics
Cancer research
Gene expression
Biochemistry
Confidence interval
Bioinformatics
Computational biology
Hazard ratio
Chemotherapy
Mutation
Gene signature
Neoadjuvant therapy
Proportional hazards model
Pathology
Chemistry
Germline mutation
Gynecology
Paleontology
Computer science
Estrogen receptor
Environmental health
Gene expression profiling
Population